ABK Biomedical, a company dedicated to the research, development and commercialisation of innovative embolic therapies, has announced the appointment of Michael J Mangano as president and chief executive officer.
Mangano will be responsible for leading global business activities, including the rapid development, regulatory approval and commercialisation of ABK’s unique medical device technologies.
Mangano most recently served as president and CEO of ReShape Medical, a US venture-backed company focused on obesity where he increased organizational value and played a lead role in orchestrating the sale of the company to EnteroMedics in October 2017. Prior to ReShape, Mangano was president of the Americas for Sirtex Medical, a leading publicly traded Australian biomedical company, where he grew the business nearly five-fold from US$30million to more than US$140 million while building a team of 17 to more than 130 employees in a period of six years. His leadership resulted in a dramatic increase in the company’s valuation, leading to the recently announced acquisition in progress of Sirtex Medical by CDH Investments for US$1.4B USD, a press release from ABK Biomedical. Prior to Sirtex, Mangano spent 15 years with Boston Scientific in numerous senior management roles, including overseas assignments in Japan and Australia.
Mangano will continue to serve on the ABK board of directors.
“I am excited to join the team at ABK, which has outstanding experience in the medical device industry. The talent at ABK, coupled with an innovative technology platform and pipeline, provide a strong foundation and solid prospects for our future growth and success,” said Mangano. “I especially look forward to working with the interventional radiology and oncology communities to develop and market novel technologies that will help patients and physicians, and want to thank the founders and the board of ABK for their support.”
Bob Abraham, co-founder and former CEO, is a practicing interventional radiologist and will remain with the company as chief medical officer. He will continue to play a key role in product development and the clinical evolution of ABK’s key technology platforms.
ABK Biomedical is organised to research, develop and commercialise breakthrough medical device therapies to improve treatment outcomes and the lives of patients with benign and malignant hypervascular tumours. Specifically, it holds intellectual property in the focus area of inorganic polymer microspheres, targeted at the growing field of embolotherapy within the interventional radiology/interventional oncology medical disciplines.